Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19471219 | 0.93 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3SIGMAR1LMNA | |
| SCHEMBL17861157 | 0.93 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3SIGMAR1LMNA | |
| SCHEMBL17861135 | 0.93 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3SIGMAR1LMNA | |
| SCHEMBL4910683 | 0.87 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3SIGMAR1LMNA | |
| SCHEMBL17861123 | 0.86 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3SIGMAR1LMNA | |
| SCHEMBL17847839 | 0.85 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3SIGMAR1LMNA | |
| SCHEMBL17861155 | 0.85 | SLC6A4 (0.57) | SLC6A2SLC6A4SLC6A3SIGMAR1LMNA | |
| SCHEMBL19471188 | 0.85 | SLC6A4 (0.57) | SLC6A2SLC6A4SLC6A3SIGMAR1LMNA | |
| SCHEMBL19471207 | 0.85 | SLC6A4 (0.57) | SLC6A2SLC6A4SLC6A3SIGMAR1LMNA | |
| SCHEMBL17861152 | 0.85 | LMNA (0.39) | SLC6A2SLC6A4SLC6A3SIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | claimed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | claimed |
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS S.A. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| EP-3233805-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096127-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096127-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | SLC6A2 1232/4885SLC6A4 679/4885SLC6A3 961/4885 |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | SLC6A2 1129/4885SLC6A4 655/4885SLC6A3 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.